再生元制药在肿瘤领域寻求突破，采取了正面竞争的策略，计划将LIBTAYO与Lag3组合进行临床试验，与现有先发药物进行头对头比较，目标是超越现有治疗方案，在疗效和生存率方面取得显著优势。再生元制药计划与Keytruda进行对比试验，并与Bristol-Myers Squibb的Opdualag进行正面PK，最终目标是实现总体生存率的提升，并与现有药物区分开来。

🤔再生元制药肿瘤领域面临挑战：作为后发者，需要正面击败先发者才能取得突破。

💪再生元制药的策略：将LIBTAYO与Lag3组合进行临床试验，与现有先发药物进行头对头比较，目标是超越现有治疗方案。

🎯再生元制药的具体计划：与Keytruda进行对比试验，并与Bristol-Myers Squibb的Opdualag进行正面PK，最终目标是实现总体生存率的提升，并与现有药物区分开来。

📈再生元制药的期望：通过临床试验数据，证明LIBTAYO+Lag3组合在疗效和生存率方面优于现有药物，并最终实现肿瘤领域逆袭。

🚀再生元制药的未来：如果临床试验结果如预期，将为再生元制药在肿瘤领域带来新的突破，并为患者带来新的治疗希望。

🏆再生元制药的竞争优势：再生元制药通过头对头PK，正面击败先发者，展现了其强大的竞争实力和对肿瘤领域的信心。

来源：雪球App，作者： 张小丰，（https://xueqiu.com/9518372158/303849518）

$再生元制药(REGN)$ 肿瘤海外后发者想要逆袭只能靠头对头PK，正面击败先发者。LIBTAYO +Lag3 vs K+chemo，LIBTAYO +Lag3 vs Opdualag（O+Lag3）

So we're excited to see what the Phase III data looks like next year, which uses pembrolizumab as the control. So we'll be testing Inmazeb plus LIBTAYO versus pembro-monotherapy. We also have a head-to-head study underway that combines our Inmazeb LIBTAYO and compares it to Opdualag, the approved LAG-3 PD-1 combination from Bristol-Myers. That trial just got underway and we'll be enrolling -- we are enrolling now and hope to get data, I think in 2026.

The primary endpoint there is objective response rate. We'll also be evaluating PFS and OS. One thing that we're really hopeful for in the KEYTRUDA-controlled study is to achieve overall survival, which was an endpoint that Opdualag missed in its metastatic melanoma program. And really, I think is an important one that if we can demonstrate we'll differentiate us beyond just the head-to-head data we hope to generate.